Semaglutide is a single GLP-1 receptor agonist
However, at higher doses, niacinamide can cause: Mild GI upset (which could theoretically compound semaglutide GI effects) Easy bruising or increased bleeding from wounds Liver enzyme elevations at very high doses (typically above 3 grams daily, far exceeding injectable doses) The 2 mg per injection dose is so low relative to studied therapeutic ranges that these side effects are essentially irrelevant for the compounded formulation
Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality prior to dispensing
Until regulators complete their review, retatrutide should not be used outside an authorised clinical trial
These studies collectively highlight the importance of reduced GSH in mitigating oxidative stress and its potential as a biomarker for oxidative damage
However, the relationship between stress and the development of Graves disease is complex and not fully understood